SARM1 and autosomal dominant optic atrophy: In fact, emerging SARM1-directed therapies, such as small-molecule SARM1 inhibitors, ASOs, and gene-therapy approaches that target SARM1), may be applied to the treatment of ADOA due to the role of SARM1 activation in ADOA pathogenesis (65).